(4) medical decision analysis related to the Bunker Hill site. Scientists with expertise specific to the health outcomes under consideration will convene to define appropriate screening tests to be included in the medical monitoring program based on the proposed outcomes and eligible populations. Also, the workshop will provide ATSDR guidance in the development of clinical evaluation protocols that could be included in a medical monitoring program.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Vivian Rush, M.D., Medical Officer, ATSDR, Division of Health Education and Promotion, 1600 Clifton Road, NE, M/S E–33, Atlanta, Georgia 30333, telephone 404/639–5080 or Gregory Thomas, Senior Regional Representative, ATSDR Region X, Seattle, WA 98101, telephone 206/553–2113.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24637 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meetings

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following Fetal Alcohol Syndrome (FAS) Prevention meetings:

Name: 1997 Fetal Alcohol Syndrome (FAS) Surveillance and Prevention Grantees' Meeting.

Time And Date: 8 a.m.–5:30 p.m., September 25, 1997.

Place: Beaver Run Resort and Conference Center, 620 Village Road, Breckenridge, Colorado 80424, 970/453–6000.

Status: Open to CDC grantees conducting FAS epidemiologic surveillance and prevention projects among various States and universities. Persons in the general public wishing to participate may telephone 770/488–7268, e-mail (GCL1@cdc.gov) or fax (770/488–7361) their request.

Purpose: The annual meeting of CDC's FAS grantees is held in order to exchange information regarding the funded projects' activities and progress.

Matters To Be Discussed: Agenda items include a CDC update related to FAS epidemiologic surveillance and prevention activities, and summary reports from each of the grantees. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Gregg Leeman, Fetal Alcohol Syndrome Prevention Section, NCEH, CDC, 4770 Buford Highway, NE, MS:F15, Atlanta, Georgia 30341, telephone 770/488–7268, e-mail GCL1@cdc.gov, fax 770/488–7361.

Name: Prevention and Management: Fetal Alcohol Syndrome and Prenatal Substance Abuse, sponsored by the Colorado Fetal Alcohol and Substance Abuse Coalition and CDC's Division of Birth Defects and Developmental Disabilities.

Times And Dates: 3 p.m.–7 p.m., September 25, 1997; 7:30 a.m.–5 p.m., September 26, 1997; 7:30 a.m.–4:30 p.m., September 27, 1997.

Place: Beaver Run Resort and Conference Center, 620 Village Road, Breckenridge, Colorado 80424, 970/453–6000.

Status: Open. Persons wishing to participate in the conference may register by contacting Elizabeth Franz, telephone 303/756–8380; e-mail fasconf@aol.com; or fax 303/759–8861. The conference registration fee is $175.00.

Purpose: Conference objectives are to present: Effective models for identification of and intervention with high-risk women; current research on screening and diagnostic methods and interventions for the child prenatally exposed to alcohol; current public health and epidemiological data; current research about the effects of alcohol and other drugs on fetal development; to discuss policy, legal and criminal justice issues related to FAS; and to explore community-based prevention programs.

Matters To Be Discussed: The conference is built around six areas of emphasis: Intervention with high-risk women; Working with the FAS affected child; Public health and epidemiology; Clinical and research issues; Policy and legal issues; Community issues and prevention programs.

Contact Person For More Information: Elizabeth Franz, Colorado Fetal Alcohol and Substance Abuse Coalition Conference Office, telephone 303/756–8380, fax 303/759–8861, e-mail fasconf@aol.com.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24635 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Advisory Council for the Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.–5 p.m., October 16, 1997; 8:30 a.m.–12 p.m., October 17, 1997.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: The Council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters to be Discussed: Agenda items include follow-up discussion on issues related to isoniazid prevention therapy; discussions on scientific basis of TB vaccine; TB vaccine development and implementation; economic issues relating to TB vaccines; and developing long term goals and/or issues of ACET. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Janet Cleveland, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E–07, Atlanta, Georgia 30333, telephone 404/639–8008.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–24636 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0022]

Agency Information Collection Activities; Submission for OMB Review; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the collection of information by October 17, 1997.

ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attention: Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT: Judith V. Bigelow, Office of Information

Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1479.

SUPPLEMENTARY INFORMATION: In compliance with section 3507 of the PRA (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance:

Notice of Availability of Sample Electronic Product—21 CFR Parts 1020, 1030, 1040, and 1050 and FDA Form 2767 (OMB Control No. 0910–0048—Reinstatement)

Under sections 532 through 542 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360ii through 360ss), FDA regulates electronic products that emit radiation. Section 532 of the act directs the Secretary of the Department of Health and Human Services (the Secretary) to establish and carry out an electronic product radiation control program designed to protect the public health and safety from electronic radiation, and authorizes the Secretary to procure (by negotiation or otherwise) electronic products for research and testing purposes and to sell or otherwise dispose of such products.

FDA's Center for Devices and Radiological Health (CDRH) conducts laboratory compliance testing of products covered by regulations for product standards in parts 1020, 1030, 1040, and 1050 (21 CFR parts 1020, 1030, 1040, and 1050). The ''Notice of Availability of Sample Electronic Product'' (Form FDA 2767) is used to inform CDRH of the location of sample products that are being requested for testing to confirm that the products comply with performance standards. Form FDA 2767 is a summary form which reports information as required by parts 1020, 1030, 1040, and 1050.

FDA also uses this information to locate and select sample products to ensure conformance with regulations. In the event this information were not collected by CDRH, each manufacturer would have to respond in letter format with all the data now being recorded on Form FDA 2767, which would require more time and expense. Testing an appropriate percentage of these products to protect the public would also be hindered by the slower process.

The respondents to this collection of information are manufacturers of electronic products.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Part and Form Number	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
1020, 1030, 1040, 1050, and Form FDA 2767	145	11.03	1,600	0.09	144
Totals					144

There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA's estimates are based on actual data collected from industry over the past 3 years, where there has been an average of 1,600 annual responses to FDA from 145 respondents each year.

Dated: September 9, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–24581 Filed 9–16–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA–R–52]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimate burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Revision of a currently approved collection; *Title of Information Collection:* Conditions for Coverage of Supplier of End Stage Renal Disease (ESRD) Services and Supporting Regulations Contained in 42 CFR 405.2100–2171; *Document No.:* HCFA–R–52 (OMB#0938–0386); *Use:* These conditions of coverage are needed to ensure proper distribution and effective utilization of ESRD treatment sources. In addition, the conditions maintain and improve the efficient delivery of care by physicians and dialysis facilities; *Frequency:* Annually; *Affected Public:* Business or other for-profit, and Federal Government; *Number of Respondents:* 2,976; *Total Annual Responses:* 2,976, *Total Annual Hours:* 100,937.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, E-mail your request, including your address, phone number, OMB number, and HCFA document identifier to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comment and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards, Attention: Louis Blank, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland, 21244–1850.

Dated: September 10, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards.

[FR Doc. 97–24652 Filed 9–16–97; 8:45 am]

BILLING CODE 4120–03–M